Advanced Viral granted patent for HIV drug

This patent is the first granted to Advanced Viral Research (ADVR) in Europe. ADVR has an extensive portfolio of the US and foreign patents including 22 issued in the US and abroad, and 32 patents pending.

Results from clinical trials conducted in Israel have shown that AVR118 may improve the quality of life of HIV patients, including increasing appetite, weight gain or stability, and activities of daily living.

Stephen Elliston, president and CEO of Advanced Viral, said: “The need for improved forms of treatment for HIV is critically important. We believe that AVR118 may help to alleviate some of the most problematic symptoms associated with this disease.”